A New Protocol and Normative Values for the Evaluation of Gastric Emptying and Gastric Accommodation to Treat Bariatric Surgery Patients

Overview

Información sobre este estudio

The purpose of this study is to establish a new protocol and normative values for evaluating gastric emptying and accommodation in bariatric surgery patients.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Able to provide written informed consent prior to any study procedures.
  • Willing and able to comply with study procedures.
  • No medical problems or chronic diseases for healthy volunteers.
  • No prior diagnosis of gastroparesis in bariatric surgery groups.
  • Body mass index of 18-27 kg/m^2 for healthy volunteers.
  • Body mass index of 18-50 kg/m^2 for bariatric surgery groups; type 2 diabetes is permissible as long as there are no exclusion criteria.
  • Female subjects must have negative urine pregnancy tests and must not be lactating prior to radiation exposure.
  • Ability and willingness to eat all components of the test meal.

Exclusion Criteria:

  • Unable or unwilling to provide informed consent.
  • Unable or unwilling to comply with study procedures.
  • Prior alteration of gastric anatomy.
  • Known or suspected gastroparesis.
  • Use of drugs known to alter gastrointestinal function including opiates, GLP1 agonists and analogs and medications known to affect gastric emptying.
  • History of recent surgery (within 60 days of screening) in the healthy volunteer group.
  • Acute or chronic illness or history of illness which in the opinion of the investigator could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data, such as frequent angina, Class III or IV congestive heart failure, moderate impairment of renal or hepatic function, poorly controlled diabetes (HbA1c >12%), etc.
  • Any clinically significant abnormalities on physical examination or laboratory abnormalities identified in the medical record, as determined by the investigator.
  • Acute GI illness within 48 hours of initiation of the baseline period.
  • Females who are pregnant or breastfeeding.
  • History of excessive alcohol use or substance abuse.
  • Any other reason, which in the opinion of the investigator, would confound proper interpretation of the study.
  • Body weight more than 600 lbs.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Michael Camilleri, M.D.

Cerrado para la inscripción

Contact information:

Kayla Arndt

(507)538-6599

Arndt.Kayla@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20445693

Mayo Clinic Footer